ATE344226T1 - Aspirin-ausgelöste lipidmediatoren - Google Patents

Aspirin-ausgelöste lipidmediatoren

Info

Publication number
ATE344226T1
ATE344226T1 AT01910912T AT01910912T ATE344226T1 AT E344226 T1 ATE344226 T1 AT E344226T1 AT 01910912 T AT01910912 T AT 01910912T AT 01910912 T AT01910912 T AT 01910912T AT E344226 T1 ATE344226 T1 AT E344226T1
Authority
AT
Austria
Prior art keywords
aspirin
lipid mediators
released lipid
released
mediators
Prior art date
Application number
AT01910912T
Other languages
English (en)
Inventor
Charles N Serhan
Clary B Clish
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE344226T1 publication Critical patent/ATE344226T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01910912T 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren ATE344226T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18307800P 2000-02-16 2000-02-16
US23881400P 2000-10-06 2000-10-06

Publications (1)

Publication Number Publication Date
ATE344226T1 true ATE344226T1 (de) 2006-11-15

Family

ID=26878731

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06022386T ATE504557T1 (de) 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren
AT01910912T ATE344226T1 (de) 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06022386T ATE504557T1 (de) 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren

Country Status (11)

Country Link
US (5) US6670396B2 (de)
EP (2) EP1762557B1 (de)
JP (5) JP4932116B2 (de)
CN (4) CN102010324B (de)
AT (2) ATE504557T1 (de)
AU (4) AU3846801A (de)
CA (1) CA2400462C (de)
DE (2) DE60144401D1 (de)
IL (1) IL151299A0 (de)
MX (1) MXPA02007915A (de)
WO (1) WO2001060778A2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL151299A0 (en) * 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
EP1268393A2 (de) * 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxinanaloge und verfahren zur behandlung von periodontalen erkrankungen
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
WO2002067988A2 (en) * 2001-02-27 2002-09-06 The Regents Of The University Of Michigan Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor
EP1406698B1 (de) * 2001-03-02 2008-10-29 The Brigham and Women's Hospital Lipoxin analoge als neue inhibitoren der angiogenese
EP1949937B1 (de) 2001-03-02 2010-05-19 The Brigham and Women's Hospital Lipoxinanaloge als neuartige Restenose-Hemmer
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
US20040176451A1 (en) * 2001-06-18 2004-09-09 Tadakazu Tamai Pparg agonistic medicinal compositions
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
AU2002365167A1 (en) * 2001-12-18 2003-07-09 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
CA2467580C (en) * 2001-12-18 2012-10-30 Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US6949664B2 (en) * 2002-04-01 2005-09-27 University Of Southern California Trihydroxy polyunsaturated eicosanoids
US7378444B2 (en) * 2002-06-17 2008-05-27 Brigham And Women's Hospital, Inc. Analogues of lipid mediators derived from omega-3 PUFAs and methods of use
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
DK2216318T3 (en) * 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bio templates for therapeutic interventions
US20040106584A1 (en) 2002-09-27 2004-06-03 Linda Arterburn Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
WO2005006878A1 (en) * 2003-07-07 2005-01-27 Hill's Pet Nutrition, Inc. Compositions for improved oxidative status in companion animals
EP1755537A4 (de) * 2004-04-14 2009-12-09 Univ Boston Verfahren und zusammensetzungen zur prävention oder behandlung von periodontopathien
US20060002985A1 (en) * 2004-07-02 2006-01-05 Zicker Steven C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
SI1799196T1 (sl) * 2004-10-08 2016-10-28 Forward Pharma A/S Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
CA2588166A1 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2007061783A1 (en) 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
EP1983977A4 (de) * 2006-01-31 2011-11-30 Martek Biosciences Corp Oxylipine aus stearidonsäure und gamma-linolensäure sowie verfahren zu ihrer herstellung und verwendung
EP2012828A2 (de) * 2006-04-28 2009-01-14 Resolvyx Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von herz-kreislauf-rkrankungen
BRPI0714562A2 (pt) * 2006-07-19 2013-04-02 Resolvyx Pharmaceuticals Inc composiÇÕes e mÉtodos para o tratamento de mucosites
EP2131833A2 (de) * 2006-10-26 2009-12-16 Resolvyx Pharmaceuticals, Inc. Verwendung von resolvinen zur hemmung von knochenschwund
US20080161275A1 (en) * 2006-12-05 2008-07-03 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
WO2009006668A1 (en) * 2007-02-05 2009-01-15 Children, Youth And Women's Health Service Modulators of antigen-dependent t cell proliferation
EP2120920A4 (de) * 2007-02-20 2011-06-15 Martek Biosciences Corp Oxylipine aus langkettigen mehrfach ungesättigten fettsäuren sowie verfahren zu ihrer herstellung und verwendung
EP2679224A1 (de) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Nitro-Ölsäuremodulation von Typ-II-Diabetes
EP2207543A2 (de) * 2007-09-14 2010-07-21 Resolvyx Pharmaceuticals, Inc. Omega-3-fettsäuren, mehrfach ungesättigte hydroxyfettsäuren, lipoxin-verbindungen oder oxylipin-verbindungen zur behandlung von autoimmunkrankheiten oder zur hemmung der immunfunktion
CN103191129A (zh) * 2007-10-12 2013-07-10 C.T.辨析有限公司 治疗眼睛病症的脂氧化物类化合物
WO2009086281A1 (en) * 2007-12-21 2009-07-09 Martek Biosciences Corporation Method for preparation of oxylipins
DK2280928T3 (en) 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
CA2734870A1 (en) * 2008-08-22 2010-02-25 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for anca-related vasculitis
ES2569371T3 (es) 2008-09-16 2016-05-10 The Brigham And Women's Hospital Inc. Compuestos del ácido 7,14-dihidroxidocosahexaenoico
WO2010039529A2 (en) * 2008-09-23 2010-04-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treament of inflammatory disease
EP2415748A4 (de) 2009-02-20 2013-08-07 Univ Tokyo Neue entzündungshemmende verbindungen
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2769624C (en) * 2009-07-31 2018-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Electrophilic fatty acid derivatives as anti-inflammatory agents
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
WO2011097276A1 (en) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Methods and compositions for treating arthritis with docosahexaenoic acid
EP2607358A4 (de) * 2010-08-19 2014-01-29 Univ Tokyo Neues aus omega-3-fettsäuren gewonnenes entzündungshemmendes metabolit
EP2744491B1 (de) 2011-08-19 2020-07-29 The University of Utah Research Foundation Kombinationstherapie mit nitrierten lipiden und inhibitoren des renin-angiotensin-aldosteron-systems
FR2979824B1 (fr) * 2011-09-13 2026-06-26 Vetinnov Composition a usage humain ou veterinaire.
JP5969186B2 (ja) * 2011-09-15 2016-08-17 出光興産株式会社 Ｇｐｒ１１９アゴニスト並びにそれを含むインスリン分泌促進剤、血糖降下剤および糖尿病の治療または予防剤
WO2013044176A2 (en) * 2011-09-23 2013-03-28 University Of Southern California Methods and compositions for the treatment of ischemic stroke
CA2864797C (en) 2012-02-15 2022-03-22 Anida Pharma Inc. Methods of treating amyotrophic lateral sclerosis
AU2013259503B2 (en) 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
WO2014130908A1 (en) * 2013-02-22 2014-08-28 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
EP2961401B1 (de) 2013-02-28 2019-11-13 Anida Pharma Inc. Verfahren zur behandlung von ototoxizität
ES2727387T3 (es) 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
RU2685706C2 (ru) * 2014-01-10 2019-04-23 Эфиммьюн Лимитед Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением
MX375328B (es) 2014-06-04 2025-03-06 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN107438366B (zh) 2015-03-18 2022-03-15 福塞斯儿童牙科医院 使用脂氧素、消退素及其类似物稳定动脉粥状硬化斑块的方法
US10047033B2 (en) 2015-05-13 2018-08-14 Ds Biopharma Limited Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
CN112245420A (zh) * 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
CN113440506A (zh) 2015-10-02 2021-09-28 康普莱克夏公司 使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病
WO2017077528A2 (en) 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
AU2016370626B2 (en) 2015-12-18 2020-08-20 Afimmune Limited Compositions comprising 15-HEPE and methods of using the same
EP3463419A4 (de) 2016-05-27 2020-03-25 Forsyth Dental Infirmary for Children Zusammensetzungen und verfahren zur behandlung von krebs unter verwendung von lipidagonisten und rezeptoren davon
KR102437682B1 (ko) 2016-06-03 2022-08-29 테티스 파마수티컬스 엘엘씨 특화된 사전 해소 매개체의 염에 관한 조성물 및 방법
CN105924338B (zh) * 2016-06-17 2019-03-01 中科瑞奥能源科技股份有限公司 丁醇尾气回收工艺与系统
EP3475442B1 (de) * 2016-06-23 2024-10-23 The Regents of The University of Michigan 12(s)-hydroxyeicosatriensäure-verbindungen und deren verwendung als therapeutika
US11439615B2 (en) 2017-03-09 2022-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2019182191A1 (ko) 2018-03-21 2019-09-26 경북대학교 산학협력단 C0x2 아세틸화제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
BR112020024019A2 (pt) 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
CA3114750A1 (en) 2018-10-09 2020-04-16 University Of Rochester Treatment of vulvovaginal disorders
US20210392935A1 (en) * 2018-11-30 2021-12-23 Evonik Operations Gmbh Preparation comprising a probiotic strain of the genus bacillus megaterium and a polyunsaturated fatty acid component
US20220226270A1 (en) * 2019-04-04 2022-07-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
WO2021054778A1 (ko) * 2019-09-20 2021-03-25 경북대학교 산학협력단 Cox2 단백질의 아세틸화 검출용 항체 및 이의 용도
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
BR112022020012A2 (pt) * 2020-04-03 2022-12-13 Afimmune Ltd Composições que compreendem 15-hepe e métodos de tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
KR20240150603A (ko) 2022-03-03 2024-10-15 테티스 파마수티컬스 엘엘씨 특수화된 해소촉진 매개체의 시클로덱스트린 복합체
WO2025023183A1 (ja) * 2023-07-21 2025-01-30 国立大学法人大阪大学 炎症性腸疾患を抑制する脂肪酸代謝産物

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466701A (en) * 1892-01-05 Hiram ezkiel payne
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
GB2033745B (en) * 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
US4567290A (en) 1981-11-27 1986-01-28 Research Corporation Leukotriene analogues
US4442099A (en) 1981-11-27 1984-04-10 Research Corporation Leukotriene analogues
US4576758A (en) 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4759880A (en) 1984-09-27 1988-07-26 Research Corporation Alkanoarachidonic acids
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US4710521A (en) 1986-07-25 1987-12-01 The Celotex Corporation Catalyst mixtures for polyisocyanurate foam
US4810424A (en) * 1987-10-09 1989-03-07 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados
US5136501A (en) 1989-05-26 1992-08-04 Reuters Limited Anonymous matching system
EP0573423A4 (en) 1990-05-07 1994-06-01 Barry I Bockow Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof
JPH0425036A (ja) 1990-05-16 1992-01-28 Mitsubishi Electric Corp マイクロ波半導体装置
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US5087790A (en) 1991-06-12 1992-02-11 University Of Southern California Method for olefination of carbonyl compounds using titanocene derivatives
CA2112399C (en) 1991-06-24 2004-06-29 Antonio Ferrante Methods and compositions for treating malaria and other diseases
US5177046A (en) 1991-09-20 1993-01-05 Air Products And Chemicals, Inc. Amine-boron adducts as reduced odor catalyst compositions for the production of polyurethanes
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
US5409955A (en) * 1993-05-13 1995-04-25 Bockow; Barry I. Compositions and methods for inhibiting uterine contractility
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
JP2536436B2 (ja) 1993-11-19 1996-09-18 日本電気株式会社 モ―ルド型半導体装置
US6030917A (en) 1996-07-23 2000-02-29 Symyx Technologies, Inc. Combinatorial synthesis and analysis of organometallic compounds and catalysts
US5752238A (en) 1994-11-03 1998-05-12 Intel Corporation Consumer-driven electronic information pricing mechanism
US5594732A (en) 1995-03-03 1997-01-14 Intecom, Incorporated Bridging and signalling subsystems and methods for private and hybrid communications systems including multimedia systems
US5801280A (en) 1995-04-07 1998-09-01 Sumitomo Chemical Company, Limited Processes for preparing optically active alcohols and optically active amines
US5845265A (en) 1995-04-26 1998-12-01 Mercexchange, L.L.C. Consignment nodes
US5756789A (en) 1995-06-08 1998-05-26 Texaco, Inc. Synthesis of metal--containing aluminophosphates with layered structure
CA2182851A1 (en) 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
US5709855A (en) * 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US5870717A (en) 1995-11-13 1999-02-09 International Business Machines Corporation System for ordering items over computer network using an electronic catalog
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
GEP20032998B (en) 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
US5878400A (en) 1996-06-17 1999-03-02 Trilogy Development Group, Inc. Method and apparatus for pricing products in multi-level product and organizational groups
US5842040A (en) 1996-06-18 1998-11-24 Storage Technology Corporation Policy caching method and apparatus for use in a communication device based on contents of one data unit in a subset of related data units
US6232467B1 (en) 1996-06-28 2001-05-15 University Of Southern California Method for the synthesis of amines and amino acids with organoboron derivatives
US6602817B1 (en) 1998-10-23 2003-08-05 University Of Southern California Combination approach to chiral reagents or catalysts having amine or amino alcohol ligands
US5890138A (en) 1996-08-26 1999-03-30 Bid.Com International Inc. Computer auction system
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US5896379A (en) 1996-08-26 1999-04-20 Motorola, Inc. Network node for packet switching with selective data processing and method therefor
US5912006A (en) * 1996-08-28 1999-06-15 Eboc, Inc. Compositions and methods for alleviating discomforting menstrual pain
US5946467A (en) 1996-09-20 1999-08-31 Novell, Inc. Application-level, persistent packeting apparatus and method
US20020055539A1 (en) 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
US6201022B1 (en) 1997-03-27 2001-03-13 Myorx, Inc. Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6428990B1 (en) 1997-04-11 2002-08-06 Abbott Laboratories Human desaturase gene and uses thereof
US5878423A (en) 1997-04-21 1999-03-02 Bellsouth Corporation Dynamically processing an index to create an ordered set of questions
US6030715A (en) 1997-10-09 2000-02-29 The University Of Southern California Azlactone-related dopants in the emissive layer of an OLED
US6259699B1 (en) 1997-12-30 2001-07-10 Nexabit Networks, Llc System architecture for and method of processing packets and/or cells in a common switch
AU3843999A (en) * 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
US6377937B1 (en) 1998-05-28 2002-04-23 Paskowitz Associates Method and system for more effective communication of characteristics data for products and services
US6069109A (en) 1998-07-01 2000-05-30 Union Carbide Chemicals & Plastics Technology Corporation Process for the production of half-sandwich transition metal based catalyst precursors
US6336138B1 (en) 1998-08-25 2002-01-01 Hewlett-Packard Company Template-driven approach for generating models on network services
US6336105B1 (en) 1998-11-16 2002-01-01 Trade Access Inc. System and method for representing data and providing electronic non-repudiation in a negotiations system
DE19855426A1 (de) * 1998-12-02 2000-06-08 Wolfgang Langhoff Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen
US6272474B1 (en) 1999-02-08 2001-08-07 Crisostomo B. Garcia Method for monitoring and trading stocks via the internet displaying bid/ask trade bars
US6397212B1 (en) 1999-03-04 2002-05-28 Peter Biffar Self-learning and self-personalizing knowledge search engine that delivers holistic results
JP4392473B2 (ja) 1999-03-18 2010-01-06 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ホスホリパーゼｄの活性の調節
AU4010100A (en) 1999-03-18 2000-10-04 Brigham And Women's Hospital Leukotriene b4 receptor transgenic mammals
ES2246230T3 (es) 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
ES2249257T3 (es) 1999-03-18 2006-04-01 The Brigham And Women's Hospital, Inc. Utilizacion de compuestos de lipoxina para la inhibicion de la respuesta de los neutrofilos inducida por tnf-alfa.
US6427132B1 (en) 1999-08-31 2002-07-30 Accenture Llp System, method and article of manufacture for demonstrating E-commerce capabilities via a simulation on a network
US6415270B1 (en) 1999-09-03 2002-07-02 Omnihub, Inc. Multiple auction coordination method and system
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
EP1268393A2 (de) 2000-03-20 2003-01-02 Trustees Of Boston University Lipoxinanaloge und verfahren zur behandlung von periodontalen erkrankungen
US6473314B1 (en) 2000-08-03 2002-10-29 Powerwave Technologies, Inc. RF power amplifier assembly employing multi-layer RF blocking filter
US20020074162A1 (en) 2000-12-15 2002-06-20 Bor-Ray Su Substrate layout method and structure for reducing cross talk of adjacent signals
EP1406698B1 (de) 2001-03-02 2008-10-29 The Brigham and Women's Hospital Lipoxin analoge als neue inhibitoren der angiogenese
US20040044028A1 (en) 2001-03-30 2004-03-04 Obukowicz Mark G. Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer
CA2465117C (en) 2001-11-06 2012-01-03 Brigham And Women's Hospital, Inc. Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
AU2002365167A1 (en) 2001-12-18 2003-07-09 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
CA2467580C (en) 2001-12-18 2012-10-30 Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US6949664B2 (en) * 2002-04-01 2005-09-27 University Of Southern California Trihydroxy polyunsaturated eicosanoids
US7582785B2 (en) 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7378444B2 (en) 2002-06-17 2008-05-27 Brigham And Women's Hospital, Inc. Analogues of lipid mediators derived from omega-3 PUFAs and methods of use
DK2216318T3 (en) 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bio templates for therapeutic interventions
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
EP1660069A4 (de) 2003-08-05 2009-03-18 Univ Louisiana State Neuroprotektion gegen zellapoptose, neurale schlaganfallschäden, alzheimer-krankheit und retinale degeneration
EP1755537A4 (de) 2004-04-14 2009-12-09 Univ Boston Verfahren und zusammensetzungen zur prävention oder behandlung von periodontopathien
US20060293288A1 (en) 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
BRPI0714562A2 (pt) 2006-07-19 2013-04-02 Resolvyx Pharmaceuticals Inc composiÇÕes e mÉtodos para o tratamento de mucosites

Also Published As

Publication number Publication date
JP2003525880A (ja) 2003-09-02
US20070049639A1 (en) 2007-03-01
CN1469858A (zh) 2004-01-21
MXPA02007915A (es) 2005-06-20
US20040059144A1 (en) 2004-03-25
AU2006225252A1 (en) 2006-11-02
JP2019108348A (ja) 2019-07-04
CN1680259A (zh) 2005-10-12
CN1202068C (zh) 2005-05-18
WO2001060778A3 (en) 2003-01-16
EP1296923A2 (de) 2003-04-02
ATE504557T1 (de) 2011-04-15
AU2006225252A2 (en) 2006-11-02
US6670396B2 (en) 2003-12-30
EP1762557A2 (de) 2007-03-14
EP1762557B1 (de) 2011-04-06
US7737178B2 (en) 2010-06-15
CN100357244C (zh) 2007-12-26
US20020055538A1 (en) 2002-05-09
JP5973503B2 (ja) 2016-08-23
AU2006225252B2 (en) 2009-02-26
JP2016006057A (ja) 2016-01-14
EP1296923B1 (de) 2006-11-02
DE60124256T3 (de) 2012-09-20
DE60124256T2 (de) 2007-05-31
DE60124256D1 (de) 2006-12-14
AU2009202071B2 (en) 2011-07-07
IL151299A0 (en) 2003-04-10
CN102010324B (zh) 2014-04-02
US7709669B2 (en) 2010-05-04
JP2010248213A (ja) 2010-11-04
CN1951899B (zh) 2012-02-01
CA2400462C (en) 2011-09-27
US7053230B2 (en) 2006-05-30
US20090149538A1 (en) 2009-06-11
WO2001060778A2 (en) 2001-08-23
JP4932116B2 (ja) 2012-05-16
AU3846801A (en) 2001-08-27
AU2001238468B2 (en) 2006-07-06
CN102010324A (zh) 2011-04-13
CA2400462A1 (en) 2001-08-23
HK1105948A1 (en) 2008-02-29
JP2015007046A (ja) 2015-01-15
WO2001060778A9 (en) 2002-10-24
EP1762557A3 (de) 2007-11-07
DE60144401D1 (de) 2011-05-19
AU2009202071A1 (en) 2009-06-18
US8349896B2 (en) 2013-01-08
CN1951899A (zh) 2007-04-25
EP1296923B3 (de) 2012-04-11
US20100216882A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
DE60124256D1 (de) Aspirin-ausgelöste lipidmediatoren
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
ITMI20001317A0 (it) Procedimento per la purificazione di diacereina.
ES1048243Y (es) Maquina para la prepoda de arboles.
NL1014850A1 (nl) Grafkist.
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.
ITSV20010001U4 (it) Vedi invenzione n. 16 del 1998
BR8101523Y1 (pt) disposição construtiva aplicada à cadeira.
ITTO20000851A0 (it) Composizione farmaceutica per il trattamento della malaria.
BR8001273Y1 (pt) suspensório médico.
TH103000048A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000015A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000020A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000315A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000088A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000058A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000734A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000021A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000003A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000093A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000016A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000030A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000004A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000023A (th) สิทธิบัตรยังไม่ประกาศโฆษณา

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties